BU Fundamental Analysis - BURCON NUTRASCIENCE CORP

Fundamental Rating

Overall BU gets a fundamental rating of 2 out of 10. We evaluated BU against 27 industry peers in the Chemicals industry. BU has a bad profitability rating. Also its financial health evaluation is rather negative. BU is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

BU had negative earnings in the past year.

In the past year BU has reported a negative cash flow from operations.

BU had negative earnings in each of the past 5 years.

BU had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -45.26%, BU is not doing good in the industry: 74.07% of the companies in the same industry are doing better.

BU has a Return On Equity of -8604.73%. This is in the lower half of the industry: BU underperforms 74.07% of its industry peers.

		Industry Rank	Sector Rank
ROA	-45.26%
ROE	-8604.73%
ROIC	N/A

ROA(3y)-113.59%

ROA(5y)-75.48%

ROE(3y)-292.02%

ROE(5y)-182.82%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BU does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, BU has more shares outstanding

Compared to 5 years ago, BU has more shares outstanding

BU has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -9.46, we must say that BU is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -9.46, BU is not doing good in the industry: 70.37% of the companies in the same industry are doing better.

BU has a Debt/Equity ratio of 104.05. This is a high value indicating a heavy dependency on external financing.

BU has a worse Debt to Equity ratio (104.05) than 74.07% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	104.05
Debt/FCF	N/A
Altman-Z	-9.46

ROIC/WACCN/A

WACC6.11%

2.3 Liquidity

BU has a Current Ratio of 0.25. This is a bad value and indicates that BU is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.25, BU is doing worse than 77.78% of the companies in the same industry.

BU has a Quick Ratio of 0.25. This is a bad value and indicates that BU is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of BU (0.21) is worse than 77.78% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.25
Quick Ratio	0.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.63%.

The Revenue has grown by 190.04% in the past year. This is a very strong growth!

Measured over the past years, BU shows a very strong growth in Revenue. The Revenue has been growing by 66.28% on average per year.

EPS 1Y (TTM)-163.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.35%

Revenue 1Y (TTM)190.04%

Revenue growth 3Y30.91%

Revenue growth 5Y66.28%

Sales Q2Q%792.98%

3.2 Future

Based on estimates for the next years, BU will show a very strong growth in Earnings Per Share. The EPS will grow by 224.01% on average per year.

Based on estimates for the next years, BU will show a very strong growth in Revenue. The Revenue will grow by 228.16% on average per year.

EPS Next Y-803.01%

EPS Next 2Y224.01%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year153.85%

Revenue Next 2Y228.17%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

The Price/Forward Earnings ratio is 0.27, which indicates a rather cheap valuation of BU.

Compared to the rest of the industry, the Price/Forward Earnings ratio of BU indicates a rather cheap valuation: BU is cheaper than 100.00% of the companies listed in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, BU is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.27

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BU's earnings are expected to grow with 224.01% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y224.01%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BU!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BURCON NUTRASCIENCE CORP

TSX:BU (11/28/2025, 7:00:00 PM)

1.8

+0.02 (+1.12%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)11-12 2025-11-12/amc

Earnings (Next)02-12 2026-02-12

Inst Owners5.92%

Inst Owner ChangeN/A

Ins Owners30.89%

Ins Owner ChangeN/A

Market Cap22.84M

Revenue(TTM)803.70K

Net Income(TTM)-11.11M

Analysts84.44

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-359.08%

Min EPS beat(2)-443.69%

Max EPS beat(2)-274.48%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)17.69%

Min Revenue beat(2)-30.64%

Max Revenue beat(2)66.02%

Revenue beat(4)1

Avg Revenue beat(4)-37.08%

Min Revenue beat(4)-95.36%

Max Revenue beat(4)66.02%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	0.27
P/S	28.42
P/FCF	N/A
P/OCF	N/A
P/B	176.93
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.98

EYN/A

EPS(NY)6.58

Fwd EY365.65%

FCF(TTM)-0.62

FCFYN/A

OCF(TTM)-0.56

OCFYN/A

SpS0.06

BVpS0.01

TBVpS-0.09

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-45.26%
ROE	-8604.73%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-113.59%

ROA(5y)-75.48%

ROE(3y)-292.02%

ROE(5y)-182.82%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	104.05
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	46.09%
Cap/Sales	95.93%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.25
Quick Ratio	0.21
Altman-Z	-9.46

F-Score4

WACC6.11%

ROIC/WACCN/A

Cap/Depr(3y)68.17%

Cap/Depr(5y)195.49%

Cap/Sales(3y)82.83%

Cap/Sales(5y)124.04%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-163.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%15.35%

EPS Next Y-803.01%

EPS Next 2Y224.01%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)190.04%

Revenue growth 3Y30.91%

Revenue growth 5Y66.28%

Sales Q2Q%792.98%

Revenue Next Year153.85%

Revenue Next 2Y228.17%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-1.09%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year40.58%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-51.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-46.69%

OCF growth 3YN/A

OCF growth 5YN/A

BURCON NUTRASCIENCE CORP / BU.CA FAQ

What is the fundamental rating for BU stock?

ChartMill assigns a fundamental rating of 2 / 10 to BU.CA.

Can you provide the valuation status for BURCON NUTRASCIENCE CORP?

ChartMill assigns a valuation rating of 3 / 10 to BURCON NUTRASCIENCE CORP (BU.CA). This can be considered as Overvalued.

How profitable is BURCON NUTRASCIENCE CORP (BU.CA) stock?

BURCON NUTRASCIENCE CORP (BU.CA) has a profitability rating of 0 / 10.

What is the earnings growth outlook for BURCON NUTRASCIENCE CORP?

The Earnings per Share (EPS) of BURCON NUTRASCIENCE CORP (BU.CA) is expected to decline by -803.01% in the next year.

BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BURCON NUTRASCIENCE CORP / BU.CA FAQ

What is the fundamental rating for BU stock?

Can you provide the valuation status for BURCON NUTRASCIENCE CORP?

How profitable is BURCON NUTRASCIENCE CORP (BU.CA) stock?

What is the earnings growth outlook for BURCON NUTRASCIENCE CORP?